Europe — EMA

Osvyrti Accord Healthcare (Denosumab)

Denosumab, the active ingredient in Osvyrti Accord Healthcare, is a presented as a for subcutaneous use. It treats osteoporosis and bone loss conditions in postmenopausal women and men at high risk.

Denosumab

Request sourcing

Pack/s

What is Denosumab?

Denosumab, the active ingredient in Osvyrti Accord Healthcare, is a presented as a for subcutaneous use. It treats osteoporosis and bone loss conditions in postmenopausal women and men at high risk.

GNH USA supplies Osvyrti Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

What is Denosumab used for?

Denosumab works """ " """ "

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →